Clinical trials: Cardiovascular Disorders
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Right Bundle-Branch Block
Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)
Heart failure (HF) affects 5 million Americans and is responsible for more health-care expenditure than any other medical diagnosis.
- Trial name
- PACE-RBBB (NCT01169493)
- Testing
- VVI-40, RV DDD-40, BiV DDD-40
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Venous Thromboembolism, Venous Thrombosis
Educating Nurses About Venous Thromboembolism (VTE) Prevention
As part of mandatory on-going nursing education, the investigators have incorporated identical information into two distinct web-based learning formats - the traditional linear PowerPoint format (with voice-over) and a new…
- Trial name
- NCT02301793
- Testing
- Nurse education in contemporary format, Nurse education in traditional format
- Where
- United States
- Volunteers
- 933 people
- Sponsor
- Johns Hopkins University
Atherosclerotic Cardiovascular Disease
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with…
- Trial name
- V-INITIATE (NCT04929249)
- Testing
- Inclisiran
- Where
- 43 sites in United States
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Arrhythmogenic Right Ventricular Cardiomyopathy
Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited arrhythmia disorder with high risk of ventricular tachycardia or fibrillation, and implantable cardioverter defibrillator remains as therapy of choice.
- Trial name
- NCT03685149
- Testing
- Flecainide Pill
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Von Willebrand Disease
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.
- Trial name
- NCT00555555
- Testing
- Alphanate SD/HT
- Volunteers
- 4 people
- Sponsor
- Grifols Biologicals, LLC
Cerebrovascular Disease
The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease.
- Trial name
- NCT01321749
- Testing
- Remote ischemic preconditioning (RIPC)
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Capital Medical University
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Coronary Artery Disease
The ROB-OSTIAL Study
The purpose of this study is to compare the accuracy of robotic-assisted percutaneous coronary intervention (PCI) using the CorPath GRX® System, versus standard PCI when treating ostial lesions.
- Trial name
- NCT05634538
- Testing
- Robotic-assisted PCI with Corpath GRX® System, Standard PCI
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Thromboembolism
A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted…
- Trial name
- NCT02913326
- Testing
- Dabigatran etexilate, Warfarin
- Where
- 36 sites in France, Germany and 7 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Cardiovascular Disease
Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension
Angiotensin Therapeutic Vaccine (ATV), which contains the novel adjuvant, CoVaccine HT™ , is being developed for the treatment of high blood pressure (hypertension), a major risk factor for serious diseases such as heart attacks…
- Trial name
- NCT00702221
- Testing
- Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant, CoVaccine HT™ adjuvant
- Where
- 12 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- BTG International Inc.
Acute Coronary Syndrome, Chest Pain
Randomized Investigation of Chest Pain Diagnostic Strategies
Clinical decision units (CDUs) improve resource utilization and are a recommended care option by the American College of Cardiology / American Heart Association, but are underutilized in non-low risk chest pain patients due to…
- Trial name
- NCT01035047
- Testing
- Clinical decision unit care, coupled with cardiac MRI
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Wake Forest University Health Sciences
Brain Neoplasms, Surgery
Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
Few studies look into cerebral blood flow (CBF) changes during emergence from general anesthesia for craniotomy. The purpose of this study is to demonstrate CBF changes during emergence from general anesthesia for craniotomy…
- Conditions
- Brain Neoplasms, Surgery, Hyperemia
- Trial name
- NCT01642147
- Testing
- Transcranial Doppler (TCD), jugular venous bulb catheterization, Tumor removal surgery under general anesthesia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Corneal Epithelial Defect, Diabetic Retinopathy
Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Ophthalmology ,cornea Autologous serum has long been known to be effective to promote corneal epithelial wound healing in a variety of ocular surface disorders.
- Conditions
- Corneal Epithelial Defect, Diabetic Retinopathy, Penetrating Keratoplasty
- Trial name
- NCT01075347
- Testing
- autologous serum, Non-autologous serum
- Where
- Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia
Postpartum Hypertension Study
The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.
- Conditions
- Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum, Hypertensive Emergency
- Trial name
- NCT05139238
- Testing
- Labetalol, Nifedipine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Columbia University
Paroxysmal Atrial Fibrillation
A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation
PEFCAT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the FARAPULSE Endocardial Ablation System for the treatment of paroxysmal atrial fibrillation.
- Trial name
- NCT03714178
- Testing
- FARAPULSE Endocardial Ablation System
- Where
- 2 sites in Czechia, France
- Volunteers
- 71 people
- Sponsor
- Boston Scientific Corporation
Myocardial Infarction
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI).
- Trial name
- VORA-PRATIC (NCT02545933)
- Testing
- Prasugrel, Vorapaxar, Aspirin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Florida
Arrhythmia, Atrial Fibrillation
Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
The objective of this study is to determine if concentrations of amiodarone in fat tissue increases constantly over time during chronic treatment with this drug, and if blood concentrations reflect accurately the concentrations…
- Conditions
- Arrhythmia, Atrial Fibrillation, Atrial Flutter
- Trial name
- ATACA (NCT00313443)
- Testing
- Fat tissue needle aspiration
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hopital Lariboisière
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.